Background: Despite the survival gain observed with antiPD-1 agents in R/M HNSCC, responses are modest and no predictive biomarkers have been validated. We investigated immune and genomic biomarkers of response in a prospective cohort of R/M HNSCC patients (pts) treated with pembrolizumab 200 mg IV Q3W in the INSPIRE study. Methods: Pts had blood samples (BS) collected at baseline (BL) and on treatment (OT) at cycle 3 (week 9); fresh tumor biopsies (FTB) collected at BL and OT (week 6-9). Analyses included tumor whole exome sequencing and immunophenotyping by flow cytometry of FTB and BS; tumor PD-L1 staining (clone 22C3) using modified proportion score. Response rate (RR) using RECIST 1.1. Median progression-free survival (PFS) and overall survival (OS) estimated by Kaplan-Meier method. Time to progression (TTP) was estimated using cumulative incidence function. Univariable analyses of genomic and immune parameters were conducted to identify response predictors. Results: Seventeen pts were enrolled: median age 62 years (48-71); smoking history > ¼10 pack-year (PY)¼ 11; oral cavity¼7, oropharynx¼6 (5 HPVþ), larynx/hypopharynx¼4. Platinum-refractory¼ 15; > ¼ 2 prior lines of therapy¼ 4; PD-L1 > ¼ 1%¼ 9. RR ¼ 3 partial responses (PR), 10 stable disease (SD), 4 progressive disease (PD). Median follow-up was 4.9 months (m)(0.6-19.3); TTP 9.7m (3.5-not-reached (NR)), PFS 4m (2.3-9.5); OS 7.9m (3.4-NR). Pts with PR had >10 PY, PD-L1 >50% and no local recurrence. Pts with PRþSD had less proliferating ki67þ, FoxP3þ T-regulatory cells (Tregs) in blood compared to PD pts (p0.05). Seven pts had FTB for analysis (1 PR, 3 SD, 3 PD): patient with PR (HPVþ oropharynx) had less immunosuppressive Tregs via lower expression of CTLA-4 and CD39 in BL tumor and increased proliferating Tregs at paired OT FTB. Tumor somatic coding mutation burden and percent genome copy alteration in FTB at BL (N ¼ 9) did not predict response (PRþSD) but a trend was observed with percent loss of heterozygosity (p0.15). Conclusions: This preliminary data suggest peripheral and tumor T-regs might play a critical role in R/M HNSCC pts treated with anti-PD1 agents. Dynamic immune-cell changes were more informative than BL genomic markers.
Background: Despite the survival gain observed with antiPD-1 agents in R/M HNSCC, responses are modest and no predictive biomarkers have been validated. We investigated immune and genomic biomarkers of response in a prospective cohort of R/M HNSCC patients (pts) treated with pembrolizumab 200 mg IV Q3W in the INSPIRE study. Methods: Pts had blood samples (BS) collected at baseline (BL) and on treatment (OT) at cycle 3 (week 9); fresh tumor biopsies (FTB) collected at BL and OT (week 6-9). Analyses included tumor whole exome sequencing and immunophenotyping by flow cytometry of FTB and BS; tumor PD-L1 staining (clone 22C3) using modified proportion score. Response rate (RR) using RECIST 1.1. Median progression-free survival (PFS) and overall survival (OS) estimated by Kaplan-Meier method. Time to progression (TTP) was estimated using cumulative incidence function. Univariable analyses of genomic and immune parameters were conducted to identify response predictors. Results: Seventeen pts were enrolled: median age 62 years (48-71); smoking history > ¼10 pack-year (PY)¼ 11; oral cavity¼7, oropharynx¼6 (5 HPVþ), larynx/hypopharynx¼4. Platinum-refractory¼ 15; > ¼ 2 prior lines of therapy¼ 4; PD-L1 > ¼ 1%¼ 9. RR ¼ 3 partial responses (PR), 10 stable disease (SD), 4 progressive disease (PD). Median follow-up was 4.9 months (m)(0.6-19.3); TTP 9.7m (3.5-not-reached (NR)), PFS 4m (2.3-9.5); OS 7.9m (3.4-NR). Pts with PR had >10 PY, PD-L1 >50% and no local recurrence. Pts with PRþSD had less proliferating ki67þ, FoxP3þ T-regulatory cells (Tregs) in blood compared to PD pts (p0.05). Seven pts had FTB for analysis (1 PR, 3 SD, 3 PD): patient with PR (HPVþ oropharynx) had less immunosuppressive Tregs via lower expression of CTLA-4 and CD39 in BL tumor and increased proliferating Tregs at paired OT FTB. Tumor somatic coding mutation burden and percent genome copy alteration in FTB at BL (N ¼ 9) did not predict response (PRþSD) but a trend was observed with percent loss of heterozygosity (p0.15). Conclusions: This preliminary data suggest peripheral and tumor T-regs might play a critical role in R/M HNSCC pts treated with anti-PD1 agents. Dynamic immune-cell changes were more informative than BL genomic markers. Clinical trial identification: NCT02644369. Legal entity responsible for the study: Princess Margaret Cancer Centre. Background: Head and neck squamous carcinoma (HNSCC) accounts for more than 600,000 cases annually worldwide. Glycosylation is the most common post-translational modification of proteins, and aberrant glycosylation is a hallmark of cancers. Core 1 b1,3-galactosyltransferase (C1GALT1) controls the crucial step in O-glycosylation and promotes malignant behavior in various cancers. However, its role in HNSCC remains unclear.
Methods:
Immunohistochemistry was performed to analyze expression of C1GALT1 in 153 HNSCC tumors. Student t-test, Kaplan-Meier analysis, and Cox-regression analyses were used to analyze correlation of C1GALT1 expression with clinicopathological factors and survivals. CRISPR/Cas9 system was used to knock out C1GALT1. MTT assay, transwell migration, and Matrigel invasion assays were carried out to evaluate HNSCC cell viability, migration, and invasion, respectively. Human phospho-RTK array and Western blot analyses were performed to evaluate signaling pathways. ELISA was used to evaluate EGF-EGFR binding affinity. Mass spectrometry was used to identify O-glycopeptides on EGFR. Molecular docking simulation was used for searching C1GALT1 inhibitors. In vivo effects of C1GALT1 and its inhibitor were evaluated in NOD/SCID mice.
Results: C1GALT1 was overexpressed in HNSCC tumors and predicts poor survivals. C1GALT1 overexpression enhanced whereas C1GALT1 knockdown/knockout suppressed cell viability, migration, and invasion in HNSCC cells. Mechanistically, C1GALT1 modulated O-glycosylation of EGFR and enhanced EGF-EGFR binding affinity, leading to increased EGFR signaling and malignant phenotypes. Using mass spectrometry, we identified five O-glycopeptides on EGFR, among which four are within the ligand binding domain. Itraconazole, a C1GALT1 inhibitor, directly bound to C1GALT1 and changed O-glycans on cell surfaces and EGFR. Targeting C1GALT1 with CRISPR/Cas9, shRNA, or itraconazole was able to significantly suppress tumor growth in NOD/SCID mice. Conclusions: Our findings indicate C1GALT1 as an attractive therapeutic target for HNSCC. Legal entity responsible for the study: National Taiwan University Hospital. Background: Phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutations have been reported in many cancers including HNSCC. The presence of mutations have shown to associate with prognosis and might predict response to phosphoinositide 3-kinase (PI3K) inhibitors. However, the frequency of mutations is various among primary tumor locations, so this might be relevant to distinguish the possibility of treatments and outcomes among HNSCC. In this study, we examined the frequency of PIK3CA mutations in patients with oral cavity and hypopharyngeal carcinoma.
Methods: Ninety-six fresh biopsies consisted of 73 oral cavity and 23 pyriform sinus carcinoma were collected for DNA extraction. DNA samples were first investigated to ascertain a reference mutational points in PIK3CA exons 4, 9 and 20. We subsequently designed two probes labelled with two different fluorescent dyes for the wild-type and mutated alleles. Mutational analysis was further carried out by using allele-specific real time PCR.
Results: We identified mutations in 10% of patients (10 out of 96 HNSCC specimens). Among 10 mutant specimens, there were 5 missense mutations (2 samples in exon 9 (E545K) and 3 samples in exon 20 (H1047R)), and 5 silence mutation in exon 20 (T1025T). None of mutation was found in exon 4. Exon 9 mutation was detected in 2 out of 96 cases and was merely from hypopharyngeal carcinoma. In exon 20, 8 mutations were found (2 hypopharyngeal carcinoma and 6 oral cavity carcinoma). Overall frequency of mutations in three exons were 8% and 17% in oral cavity and hypopharyngeal carcinoma, respectively. 
